<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Small, Gary W.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The Treatment of Alzheimer's Disease: Comparing Guidelines</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">30-31</style></pages><abstract><style  face="normal" font="default" size="100%">It is projected that there will be 8.7 million patients with dementia who live in the United States by 2030 [Guttman R et al. Arch Fam Med 1999]. Alzheimer Disease (AD) is a complex, debilitating disease, and due to conflicting guidelines, there is confusion among practitioners regarding the best treatment practices for a patient who suffers from AD. Thus far, AD treatment is limited to symptomatic therapy, but prevention and disease-modifying therapy are the ultimate goals.</style></abstract><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">9</style></volume></record></records></xml>